### Edgar Filing: ANTARES PHARMA INC - Form 8-K

ANTARES PHARMA INC Form 8-K May 01, 2003

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

-----

FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 Or 15(D) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 28, 2003

Registrant's telephone number, including area code: (610) 458-6200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events and Required FD Disclsoure.

On May 1, 2003, Antares Pharma, Inc. (the "Company") announced that the Listing Qualifications arm of The Nasdaq Stock Market, Inc. had determined to delist the Company's shares of common stock from trading on The Nasdaq SmallCap Market effective May 7, 2003. The Company has requested an oral hearing with the Listing Qualifications Panel to appeal Nasdaq's determination. This hearing request will stay the delisting of the Company's common stock pending the Panel's decision.

A copy of the press release issued by the Company on May 1, 2003 is attached hereto as Exhibit 99.1

## Edgar Filing: ANTARES PHARMA INC - Form 8-K

- Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
- (c) Exhibits.
  - 99.1 Press Release dated May 1, 2003.

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 1, 2003 ANTARES PHARMA, INC.

By /s/ Lawrence M. Christian
-----Lawrence M. Christian
Chief Financial Officer

### EXHIBIT INDEX

99.1 Press Release dated May 1, 2003.